Victory Capital Management
BLPH

Victory Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Victory Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-553
Closed -$6K – 3734
2020
Q1 		$6K Buy
+553
New +$3.71K ﹤0.01% 3264
2019
Q4 		– Sell
-504
Closed -$4K – 3701
2019
Q3 		$4K Buy
+504
New +$4.6K ﹤0.01% 3539

Other funds holding BLPH

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's BLPH Position: Q2 2020 in Review

Victory Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2020, closing a stake of 553 shares — an estimated $6K sold.

Victory Capital Management first reported a position in BLPH in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 37 funds tracked by Wall St. Rank hold BLPH as of Q2 2020.

  • Victory Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 553 Bellerophon Therapeutics, Inc. shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Bellerophon Therapeutics, Inc. position peaked at $6K in Q1 2020.
  • 37 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.